AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34881510 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 44
Study 34881510 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 44
Study 32916063 — intervention group
Group type: EXPERIMENTAL
Intervention: Met+SU+Voglibose
Number of subjects: 110
Study 32916063 — intervention group
Group type: EXPERIMENTAL
Intervention: Met+Voglibose
Number of subjects: 110
Study 32026568 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (LNS) during pregnancy and 6 months postpartum
Number of subjects: 799
Study 32026568 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN) during pregnancy and 6 months postpartum (Ghana only)
Number of subjects: 799
Study 32026568 — intervention group
Group type: COMPARATOR
Intervention: Iron plus folic acid (IFA) during the index pregnancy (Ghana) or during and for 3 months after the index pregnancy (Bangladesh)
Number of subjects: 799
Study 36506062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 3480
Study 36506062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cancer-specific survival (CSS)
Number of subjects: 3480
Study 36506062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting 1-, 3-, and 5-year OS rates
Number of subjects: 3480
Study 36506062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for clinical decision-making
Number of subjects: 3480
Study 36163945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 53
Study 36163945 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study 33689606 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B (Air Optix Aqua, Ciba Vision)
Number of subjects: 49
Study 33689606 — intervention group
Group type: COMPARATOR
Intervention: Balafilcon A (Pure Vision 2 HD, Bausch+Lomb)
Number of subjects: 49
Study 33689606 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lenses
Number of subjects: 49
Study 33050931 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 7020
Study 33050931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 33050931 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 35998300 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC-pembrolizumab
Number of subjects: 692
Study 35998300 — intervention group
Group type: COMPARATOR
Intervention: Placebo-pembrolizumab
Number of subjects: 692
Study 34389547 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus point‐of‐care PlGF testing
Number of subjects: 2313
Study 34389547 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2313
Study 32014806 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion over 30-45 min
Number of subjects: 11
Study 32014806 — intervention group
Group type: COMPARATOR
Intervention: Standard platelet transfusion over 2-4 h
Number of subjects: 11
Study 34809475 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary basal rate and extended bolus features in addition to basal insulin modifications
Number of subjects: 30
Study 34809475 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin adjustments only
Number of subjects: 30
Study 32750143 — intervention group
Group type: EXPERIMENTAL
Intervention: abemaciclib + ET
Number of subjects: 1138
Study 32750143 — intervention group
Group type: COMPARATOR
Intervention: placebo + ET
Number of subjects: 1138
Study 32223446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 32223446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 34420200 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-containing amino acid supplement (LGA group)
Number of subjects: 37
Study 34420200 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 37
Study 35966733 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needle acupuncture plus Xitong Waixi lotion
Number of subjects: 80
Study 35966733 — intervention group
Group type: COMPARATOR
Intervention: Xitong Waixi lotion
Number of subjects: 80
Study 33449836 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Banded Sleeve Gastrectomy (LBSG)
Number of subjects: 209
Study 35401060 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day workshop on blood pressure and reducing salt consumption for health personnel and an eight-session workshop for mothers on reducing salt intake and blood pressure.
Number of subjects: 200
Study 35785965 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based regular exercise (EXE)
Number of subjects: 47
Study 35785965 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based regular exercise and 15-min postexercise sauna (EXS)
Number of subjects: 47
Study 35785965 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 47
Study 33243443 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus EP-100 (80 mg/m2 paclitaxel intravenously plus 30 mg/m2 EP-100 intravenously)
Number of subjects: 44
Study 33243443 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone (80 mg/m2 intravenously)
Number of subjects: 44
Study 33243443 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus EP-100
Number of subjects: 44
Study 33243443 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 44
Study 34103439 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg daily)
Number of subjects: 31
Study 34103439 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 31
Study 33407801 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 7.5 mg QD
Number of subjects: 197
Study 33407801 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg QD
Number of subjects: 197
Study 33407801 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg QD
Number of subjects: 197
Study 33407801 — intervention group
Group type: COMPARATOR
Intervention: upadacitinib (all doses) after switching from placebo
Number of subjects: 197
Study 33407801 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg and 30 mg
Number of subjects: 197
Study 33407801 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 7.5 mg and 15 mg
Number of subjects: 197
Study 36383809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (bolus 0.5 mcg/kg followed by 0.7 mcg/kg/h)
Number of subjects: 24
Study 32198604 — intervention group
Group type: EXPERIMENTAL
Intervention: Musicians
Number of subjects: 0
Study 32198604 — intervention group
Group type: COMPARATOR
Intervention: Nonmusicians
Number of subjects: 0
Study 34119443 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines-based clinical pathway of care
Number of subjects: 0
Study 34119443 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 32819780 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT LOUD
Number of subjects: 8
Study 33839465 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and potassium thiocyanate with standard treatment of SCA (test group, N = 14)
Number of subjects: 21
Study 33839465 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (control group, N = 7)
Number of subjects: 21
Study 33135390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg with famotidine
Number of subjects: 0
Study 33135390 — intervention group
Group type: COMPARATOR
Intervention: Lemborexant 10 mg
Number of subjects: 0
Study 36192754 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAMWork mobile application
Number of subjects: 0
Study 36192754 — intervention group
Group type: COMPARATOR
Intervention: Informational paper booklet
Number of subjects: 0
Study 34412739 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential clinically significant drug-drug interactions (DDIs) detected using Lexicomp software
Number of subjects: 1211
Study 32583957 — intervention group
Group type: EXPERIMENTAL
Intervention: Umibecestat (orally active β‐secretase inhibitor)
Number of subjects: 372
Study 33353440 — intervention group
Group type: EXPERIMENTAL
Intervention: BeFAST (sports skills movement training)
Number of subjects: 20
Study 33353440 — intervention group
Group type: COMPARATOR
Intervention: BeSTRONG (lower limb strength training)
Number of subjects: 20
Study 36066332 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group-based rehabilitation program comprising goal setting, physical exercise, psychoeducation, individual follow-up consultations, and peer support.
Number of subjects: 60
Study 36066332 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise component of the rehabilitation program.
Number of subjects: 60
Study 36066332 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual consultations as part of the rehabilitation program.
Number of subjects: 60
Study 36066332 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support as part of the rehabilitation program.
Number of subjects: 60
Study 32240832 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (n = 85) for 7 days
Number of subjects: 180
Study 32240832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 95) for 7 days
Number of subjects: 180
Study 32240832 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (n = 85)
Number of subjects: 180
Study 32240832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 95)
Number of subjects: 180
Study 32661193 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated SMS intervention (2 messages per week for 3 months)
Number of subjects: 320
Study 32661193 — intervention group
Group type: COMPARATOR
Intervention: Standard of care diabetic care (control group)
Number of subjects: 320
Study 35960214 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 570
Study 35960214 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 570
Study 34063455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (from GOG218 and ICON7 studies)
Number of subjects: 0
Study 34063455 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (from SOLO-1 study)
Number of subjects: 0
Study 34063455 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (from PRIMA study)
Number of subjects: 0
Study 34063455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (from ongoing ATHENA study)
Number of subjects: 0
Study 34063455 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (PD-1 and PD-L1 antibodies)
Number of subjects: 0
Study 36216620 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational time-out intervention
Number of subjects: 8
Study 34193480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.25 mg/kg
Number of subjects: 80
Study 34193480 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 80
Study 32962684 — intervention group
Group type: COMPARATOR
Intervention: Usual practice, repeated assessments and a self-monitoring app
Number of subjects: 2142
Study 32962684 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic cognitive-behavioral therapy self-help in app
Number of subjects: 2142
Study 32962684 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised EC self-help in app
Number of subjects: 2142
Study 36206153 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flux Hemodialysis (HF-HD) with dialyzer surface area 2.6m2
Number of subjects: 25
Study 36206153 — intervention group
Group type: EXPERIMENTAL
Intervention: Online post-dilution Hemodiafiltration (HDF)
Number of subjects: 25
Study 36206153 — intervention group
Group type: COMPARATOR
Intervention: High-Flux Hemodialysis (HF-HD)
Number of subjects: 25
Study 34220825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Number of subjects: 41
Study 34220825 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 32891271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise program
Number of subjects: 28
Study 32891271 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program
Number of subjects: 28
Study 32891271 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Tai Chi and Home exercise
Number of subjects: 28
Study 33908167 — intervention group
Group type: EXPERIMENTAL
Intervention: Photography-aided behavioural intervention
Number of subjects: 55
Study 33908167 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study 32147372 — intervention group
Group type: EXPERIMENTAL
Intervention: Total adverse childhood experience score
Number of subjects: 565
Study 32147372 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 565
Study 36463629 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Control Training Program for Social Anxiety (ACTP‐SA)
Number of subjects: 30
Study 36463629 — intervention group
Group type: COMPARATOR
Intervention: Sham-intervention control condition
Number of subjects: 30
Study 34023405 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with FOG
Number of subjects: 75
Study 34023405 — intervention group
Group type: COMPARATOR
Intervention: Patients without FOG
Number of subjects: 75
Study 33001144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline, 0.1%
Number of subjects: 304
Study 33001144 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 304
Study 34628447 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + RT (3× per week, 12 weeks)
Number of subjects: 17
Study 34628447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 17
Study 34628447 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + RT
Number of subjects: 17
Study 33359106 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500-mg tablet 45 minutes before reduction
Number of subjects: 100
Study 33359106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35791295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal testosterone (NT) 11 mg TID
Number of subjects: 75
Study 35791295 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone cypionate (TC) 200 mg ×2 weeks
Number of subjects: 75
Study 35791295 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous testosterone pellets (TP) 800 mg
Number of subjects: 75
Study 33038531 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating levels of soluble ST2 (sST2)
Number of subjects: 160
Study 33038531 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic efficiency (DE) calculated as net fluid output per 40 mg of furosemide equivalents
Number of subjects: 160
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 reminder
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 reminders
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 reminders
Number of subjects: 164205
Study 32421168 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 reminder (adults 18-64 years)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 reminders (adults 18-64 years)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 reminders (adults 18-64 years)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: COMPARATOR
Intervention: No reminder (adults 18-64 years)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 reminder (male patients)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 reminders (male patients)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 reminders (male patients)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: COMPARATOR
Intervention: No reminder (male patients)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 reminder (non-Hispanic patients)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 reminders (non-Hispanic patients)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 reminders (non-Hispanic patients)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: COMPARATOR
Intervention: No reminder (non-Hispanic patients)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 reminder (not vaccinated in prior 2 years)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 reminders (not vaccinated in prior 2 years)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 reminders (not vaccinated in prior 2 years)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: COMPARATOR
Intervention: No reminder (not vaccinated in prior 2 years)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 reminder (including self-reported vaccinations)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 reminders (including self-reported vaccinations)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 reminders (including self-reported vaccinations)
Number of subjects: 164205
Study 32421168 — intervention group
Group type: COMPARATOR
Intervention: No reminder (including self-reported vaccinations)
Number of subjects: 164205
Study 33170536 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS rs‐EPI
Number of subjects: 134
Study 33170536 — intervention group
Group type: COMPARATOR
Intervention: rs‐EPI
Number of subjects: 134
Study 32691548 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of operative procedure using Two Chief Surgeons Model and anticlockwise operative process
Number of subjects: 146
Study 32691548 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific operative procedure
Number of subjects: 146
Study 32691548 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 146
Study 33952155 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 72
Study 33952155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 72
Study 33386053 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading protocol (Group A)
Number of subjects: 0
Study 33386053 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading protocol (Group B)
Number of subjects: 0
Study 33386053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 33724104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 120
Study 33724104 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted)
Number of subjects: 120
Study 34587941 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (CS-OSA)
Number of subjects: 21
Study 34587941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 34424265 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn genomic sequencing (nGS) report of childhood‐onset conditions and highly actionable adult‐onset conditions
Number of subjects: 519
Study 34424265 — intervention group
Group type: COMPARATOR
Intervention: Standard newborn screening and a family history report (control group)
Number of subjects: 519
Study 34424265 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn genomic sequencing (nGS)
Number of subjects: 519
Study 36223105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure goal of less than 120 mm Hg)
Number of subjects: 9361
Study 33411585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine/Dexamethasone pulses every 4 weeks (VCR/DEX4)
Number of subjects: 9229
Study 33411585 — intervention group
Group type: COMPARATOR
Intervention: Vincristine/Dexamethasone pulses every 12 weeks (VCR/DEX12)
Number of subjects: 9229
Study 33411585 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral methotrexate at a dose of 20 mg/m2 (MTX20)
Number of subjects: 9229
Study 33411585 — intervention group
Group type: COMPARATOR
Intervention: Weekly oral methotrexate at a dose of 40 mg/m2 (MTX40)
Number of subjects: 9229
Study 32898176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy total diet replacement (TDR) programme delivered by lay counsellors
Number of subjects: 12
Study 32898176 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and guidance from the counsellor
Number of subjects: 12
Study 32898176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid weight loss experienced by patients
Number of subjects: 12
Study 32898176 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall experience of the TDR programme
Number of subjects: 12
Study 34763950 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPIBEV™ vaccine
Number of subjects: 467
Study 34763950 — intervention group
Group type: COMPARATOR
Intervention: Havrix® vaccine
Number of subjects: 467
Study 33019730 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents with stroke prior to admission
Number of subjects: 643
Study 33019730 — intervention group
Group type: COMPARATOR
Intervention: Residents without stroke prior to admission
Number of subjects: 643
Study 35473409 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (cycle ergometer)
Number of subjects: 54
Study 35473409 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 54
Study 35473409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 33504188 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT+MT
Number of subjects: 2002
Study 33504188 — intervention group
Group type: COMPARATOR
Intervention: direct MT
Number of subjects: 2002
Study 35710560 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 60
Study 35710560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60